NEWS★ LIFE SCIENCES / BIOTECHNOV 9, 2026
SRTD raises €31.5m for more selective mRNA therapies
An mRNA treatment needs to do its work in the right cells.

An mRNA treatment needs to do its work in the right cells.
What happened
SRTD Biotech announced a €31.5m seed round, led by Mérieux Equity Partners with NRW.BANK and Boehringer Ingelheim Venture Fund as co-leads. The funding supports preclinical development of RNA therapies for cancer, autoimmune disease and fibrosis.
Why it matters
SRTD aims to activate therapeutic instructions selectively inside diseased cells. If successful, that approach could help limit unwanted activity in healthy tissue.
The bigger picture
This remains a development programme, not demonstrated clinical efficacy. Preclinical results, regulatory progress and eventual human data will determine whether the biological idea becomes a useful treatment.
